CXCL8-L
|
RCC
|
CXCL8-L
|
RCC
|
pazopanib Sensitive: C3 – Early Trials
|
pazopanib Sensitive: C3 – Early Trials
|
CXCL8-L
|
Ovarian Cancer
|
CXCL8-L
|
Ovarian Cancer
|
bevacizumab + sorafenib Sensitive: C3 – Early Trials
|
bevacizumab + sorafenib Sensitive: C3 – Early Trials
|